Nodal Staging (N2/N3) in Lung Cancer: Definitions, Prognostic Impact, and Clinical Management

N2 Disease Definition

Ipsilateral mediastinal lymph nodes (same side as the primary tumor) are classified as N2 involvement. 1
Subcarinal lymph nodes (station 7, located below the carina) are also included in the N2 category. 3
Lymph nodes are deemed abnormal when the axial short‑axis diameter exceeds 10 mm on imaging. 1
The prevalence of metastasis rises with node size: approximately 30 % for nodes measuring 10–15 mm and 67 % for nodes larger than 15 mm. 1

Contralateral mediastinal lymph nodes (opposite side of the primary tumor) are classified as N3. 1
Contralateral hilar lymph nodes are also considered N3 disease. 1
Supraclavicular or scalene nodes (station 1, extending from the lower clavicular border to the lower cricoid border) on either side are included in N3. 2

A greater number of involved nodal stations is associated with a progressively worse prognosis in lung cancer. [1][3]

N2 disease combined with T1–T3 tumors typically places the patient in Stage IIIA. 1
N3 disease corresponds to Stage IIIB when paired with T1–T2 tumors (T1‑T2 N3 M0) and to Stage IIIC when paired with T3–T4 tumors (T3‑T4 N3 M0). 1

Tissue confirmation of PET‑positive mediastinal nodes is mandatory before excluding curative surgery; the positive predictive value of PET for mediastinal involvement is 79 %, necessitating histologic or cytologic verification. 5
Axillary lymph node metastasis occurs in about 0.75 % of lung cancers but is classified as M1 disease, not part of the N descriptor. 1
The anatomical border between left and right paratracheal nodes is defined by the left lateral border of the trachea, not the midline. 4
A pulmonary nodule ≤1 cm (e.g., a 7 × 6 mm lesion) is staged as T1a; precise N staging through appropriate imaging and, when indicated, invasive procedures is essential for accurate overall stage determination and treatment planning. [1][6]